Unknown

Dataset Information

0

PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.


ABSTRACT: Background:PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson's disease. Methods:A 15-week, phase?II, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy and safety of flexible-dose PF-06649751 in subjects with early stage Parkinson's disease (ClinicalTrials.gov identifier: NCT02847650). Results:Enrollment was terminated early for reasons unrelated to the trial. Overall, 57 subjects received study medication (PF-06649751?=?29; placebo?=?28) and 47 completed the study (PF-06649751?=?25; placebo?=?22). Despite early termination, the study met its primary endpoint with the PF-06649751 group showing statistically significant improvement from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part?III score at week?15 compared with placebo. Mean (SE) change in MDS-UPDRS Part?III score was -9.0 (1.54) for PF-06649751 and -4.3 (1.65) for placebo. This corresponds to an improvement versus placebo of 4.8 for the PF-06649751 group (two-sided p?=?0.0407; 90% CI?=?1.0, 8.6). Statistically significant improvement in MDS-UPDRS-III score was also observed at all assessment time points prior to week 15. The safety profile of PF-06649751 was similar to that observed in prior studies, with the majority of adverse events (AEs) reported as mild or moderate. The most common AEs in the PF-06649751 group were nausea, headache, dry mouth, somnolence, and tremor. Conclusions:Once-daily dosing of oral PF-06649751 resulted in significant improvement of motor symptoms and was generally well tolerated in subjects with early stage Parkinson's disease.

SUBMITTER: Riesenberg R 

PROVIDER: S-EPMC7066585 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.

Riesenberg Robert R   Werth John J   Zhang Yao Y   Duvvuri Sridhar S   Gray David D  

Therapeutic advances in neurological disorders 20200306


<h4>Background</h4>PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson's disease.<h4>Methods</h4>A 15-week, phase II, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy and safety of flexible-dose PF-06649751 in subjects with early stage Parkinson's disease (ClinicalTrials.gov identifier: NCT02847650).<h4>Results</h4>Enrollment was terminated e  ...[more]

Similar Datasets

2018-04-21 | E-MTAB-6246 | biostudies-arrayexpress
| S-EPMC6282325 | biostudies-literature
| S-EPMC3902018 | biostudies-literature
| S-EPMC5838770 | biostudies-literature
2018-03-01 | GSE97248 | GEO
| S-EPMC9486635 | biostudies-literature
| S-EPMC9402607 | biostudies-literature
| S-EPMC9188333 | biostudies-literature
2015-10-01 | GSE68049 | GEO
| S-EPMC5766700 | biostudies-other